Association of Gut Microbiota and Immune Gene Expression with Response to Targeted Therapy in BRAF-mutated Melanoma
We hypothesize that gut microbiota composition may influence responses to treatment or toxicity in patients receiving BRAF/MEK therapy. Specific microorganisms may serve as prognostic or predictive biomarkers of response, as well as of treatment-related adverse events. Additionally, genes associated with immune activation could further refine prognostic and predictive models. By identifying biomarkers for early prediction of response and microorganisms linked to treatment efficacy and toxicity, our findings aim to contribute to the development of microbiota-modulation strategies that could enhance therapeutic outcomes in specific contexts.